Abstract
End-stage renal disease (ESRD) patients are known to have a high risk of developing cancer-related inflammation. Elevated serum levels of tumor markers in ESRD/hemodialysis patients makes analysis and interpretation difficult.Aim: To verify the possible relationship between chronic low-grade systemic inflammation serum levels determined by C-reactive protein (CRP) and the tumor biomarkers in patients on hemodialysis.Materials and methods: A prospective study of prevalence was conducted in the Hemodialysis Sector of the University Hospital of the University of Brasília between July 2016 and December 2016 in men aged 18 to 60 years without clinically detectable cancer. We assessed inflammation by serum high-sensitivity CRP test (hs-CRP) and serum tumor in the case groups and controls. The hemodialysis group was split into two subgroups: group 1: patients with inflammation (CRP > 5 mg/L, n=27), and group 2: patients without inflam-mation (CRP ≤5 mg/L, n=33). There was no significant difference in age mean levels between case groups and controls (44.00±08.00 vs. 41.00±07.00, p=0.08). There was no difference or correlation (p>0.05) between tumor markers levels and patients with and without inflammation.Conclusions: The results of this study suggest that chronic low-grade systemic inflammation defined by C-reactive protein serum levels does not promote elevated serum PSA levels in chronic hemodialysis patients.
Highlights
End-stage renal disease (ESRD) patients are known to have a high risk of developing cancer-related inflammation
Different studies in the past have shown that the risk of cancer development is increased in end-stage renal disease (ESRD) patients, whether on dialysis or not, when compared with the general population.[1,2]
Lin et al.[2] checked in dialysis group a significantly higher 7-year cancer incidence rate (6.4%) than did the control group and by multivariable analyses confirmed the association between long-term dialysis and cancer and concluded that dialysis is associated with a higher risk of cancer in patients with ESRD
Summary
End-stage renal disease (ESRD) patients are known to have a high risk of developing cancer-related inflammation. Conclusions: The results of this study suggest that chronic low-grade systemic inflammation defined by C-reactive protein serum levels does not promote elevated serum PSA levels in chronic hemodialysis patients. Different studies in the past have shown that the risk of cancer development is increased in end-stage renal disease (ESRD) patients, whether on dialysis or not, when compared with the general population.[1,2] Lin et al.[2] checked in dialysis (hemodialysis and peritoneal dialysis) group a significantly higher 7-year cancer incidence rate (6.4%) than did the control group and by multivariable analyses confirmed the association between long-term dialysis and cancer and concluded that dialysis is associated with a higher risk of cancer in patients with ESRD.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
